실적분석 2026년 8월 12일

STAAR Surgical ($STAA) Q2 2026 Earnings Analysis — Revenue Beat, Return to Profit, Yet After-Hours Weakness

Earnings Scorecard

Revenue: $93.5 million (YoY +111%, estimate $90.55 million) ✅ Beat

EPS: GAAP diluted $0.16 · Adjusted EBITDA per diluted share $0.39 (direct comparison with adjusted consensus $0.22 not possible due to different metric)

Guidance: Not provided — only noted expected YoY growth (excluding prior-year one-off orders) alongside seasonality (softening after H1 peak) in Q3 and Q4

Share price reaction: After-hours -4.09% ($24.37) — as of 06:00 KST, Aug 13

The Positives

Revenue beat: $93.5 million topped the $90.55 million estimate, up 111% YoY

Return to profit: Net income of $8.1 million and GAAP diluted EPS of $0.16 (exited prior-year loss)

China and U.S. recovery: China revenue $52.3 million (+10% QoQ), Americas growth of 12%

The company said there were no signs of excess inventory at China distributors or hospitals, and improved mix in Evo Plus and Toric lenses lifted average selling prices. Gross margin came in at 74.5%, modestly above 74.0% a year earlier, and quarter-end cash and short-term investments stood at $181.5 million with no debt.

The Negatives

China concentration: More than half of revenue tied to China

Second-half seasonal slowdown: Q1 and Q2 are the new peak season, with Q3 volumes expected to step down from H1

Limited direct comparability for adjusted EPS: Adjusted EBITDA per diluted share of $0.39 was disclosed, but the metric differs from the $0.22 consensus, hindering a direct comparison

Last year's Q2 had almost no shipments because of China inventory destocking, which set a low base for this year's 111% growth. Europe, the Middle East and Africa posted a low single-digit decline on Middle East impacts, and tariffs on U.S.-made products shipped to China will continue to weigh on margins until the shift to Swiss production is complete.

What Management Said

The new CEO assessed the H1 performance as progress on three pillars — revenue growth, profit expansion and faster innovation — and noted the ongoing trend of taking share from laser vision correction in China. Without issuing quantitative quarterly or annual guidance, management indicated that Q3 volumes may step down seasonally from H1, but YoY growth should hold once prior-year one-off orders are excluded.

Market Reaction and What to Watch Next

Despite the revenue beat and return to profitability, the absence of quantitative guidance combined with second-half seasonal softness and China concentration risk appears to have triggered profit-taking.

How much Q3 revenue grows versus the prior-year adjusted base of roughly $68.8 million

Whether the mix of Evo Plus and Toric in China and channel inventory remain within target ranges

Whether the move to Swiss production reduces tariff drag and lifts gross margin further